Potential clinical exploitation of the radiation-induced DNA damage response.

Symonds, R P; Jones, G D

Symonds, R P; Jones, G D.

Affiliation

Symonds RP; Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, UK.
Jones GD; Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, UK. Electronic address: gdj2@le.ac.uk.

Clin Oncol (R Coll Radiol) ; 26(5): 241-2, 2014 May.

Article in En | MEDLINE | ID: mdl-24602565

Subject(s)

DNA Damage/drug effects; DNA/radiation effects; Radiation Injuries/prevention & control; Antineoplastic Agents/pharmacology; Ataxia Telangiectasia/drug therapy; Ataxia Telangiectasia/genetics; Ataxia Telangiectasia Mutated Proteins/antagonists & inhibitors; Checkpoint Kinase 1; Checkpoint Kinase 2/antagonists & inhibitors; Chemoradiotherapy; Drugs, Investigational/pharmacology; Genes, erbB-1/drug effects; Genes, erbB-1/radiation effects; Humans; Protein Kinases/drug effects; Radiobiology/trends; Vascular Endothelial Growth Factor A/drug effects; Vascular Endothelial Growth Factor A/radiation effects

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Radiation Injuries / DNA Damage / DNA Limits: Humans Language: En Journal: Clin Oncol (R Coll Radiol) Year: 2014 Document type: Article

Fulltext

XML

PubMed Links

Search on Google